Journal of diabetes · 2026
Effects of Short-Term Intensive Insulin Therapy Combined With Oral Hypoglycemic Agents for Inducing Remission in Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Clinical Trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ke Weijian, Liu Liehua, Zhang Pengyuan, Yan Li, Zhang Qian, Zhang Fan, Xu Xuejuan, Liu Juan, Xu Lijuan, Wan Xuesi, Li Hai, Cao Xiaopei, Xiao Haipeng, Putman Melissa S, Li Yanbing
Аннотация
AIMS: To investigate the effects of combining oral hypoglycemic agents with short-term intensive insulin therapy (SIIT) via continuous subcutaneous insulin infusion (CSII) on glycemic outcomes in adults with newly diagnosed type 2 diabetes mellitus.
MATERIALS AND METHODS: In this multicenter, open-label trial, 245 participants were randomized to three treatment arms: SIIT for 2 weeks (CSII group), SIIT plus 90-day metformin and pioglitazone (CSII + Met + Pio group), or SIIT plus 90-day sitagliptin (CSII + Sita group). The primary outcome was the 12-month diabetes remission rate. Parameters of glycemic control, β-cell function, and insulin resistance were compared among groups.
RESULTS: The participants had a mean HbA1c of 10.6% ± 2.2%. Compared to the CSII group, both combination groups had lower total daily and pre-meal bolus insulin requirements with higher time in tight target range (TITR) during SIIT, and had significantly greater acute insulin response (AIR) after SIIT. Three months post SIIT, more participants in the CSII + Met + Pio group (78.7%, 59/75) achieved HbA1c < 6.5% compared with the CSII group (59.0%, 46/78; adjusted p < 0.05), but the 12-month diabetes remission rates were similar (p = 0.972).
CONCLUSIONS: Oral hypoglycemic agents facilitated SIIT implementation and enhanced transient improvements in glycemic control. However, similar 12-month diabetes remission rates suggest prolonged sequential therapy may be needed for sustained glycemic benefit.
MATERIALS AND METHODS: In this multicenter, open-label trial, 245 participants were randomized to three treatment arms: SIIT for 2 weeks (CSII group), SIIT plus 90-day metformin and pioglitazone (CSII + Met + Pio group), or SIIT plus 90-day sitagliptin (CSII + Sita group). The primary outcome was the 12-month diabetes remission rate. Parameters of glycemic control, β-cell function, and insulin resistance were compared among groups.
RESULTS: The participants had a mean HbA1c of 10.6% ± 2.2%. Compared to the CSII group, both combination groups had lower total daily and pre-meal bolus insulin requirements with higher time in tight target range (TITR) during SIIT, and had significantly greater acute insulin response (AIR) after SIIT. Three months post SIIT, more participants in the CSII + Met + Pio group (78.7%, 59/75) achieved HbA1c < 6.5% compared with the CSII group (59.0%, 46/78; adjusted p < 0.05), but the 12-month diabetes remission rates were similar (p = 0.972).
CONCLUSIONS: Oral hypoglycemic agents facilitated SIIT implementation and enhanced transient improvements in glycemic control. However, similar 12-month diabetes remission rates suggest prolonged sequential therapy may be needed for sustained glycemic benefit.